Maribavir for stubborn CMV after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether taking maribavir for different lengths of time can help treat a stubborn CMV infection after a stem cell transplant. It is for people whose CMV hasn't improved with standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had your first stem cell transplant from a donor (allogeneic) and are at least 18 years old.
- You have a CMV infection that is not getting better with standard antiviral treatment (refractory).
- You do not have active hepatitis B, HIV, or severe organ failure (like severe heart, lung, liver, or kidney problems).
- You are not allergic to maribavir or any of its ingredients.
- You do not have CMV in your brain or spinal cord, and you are able to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This study tests a medicine called maribavir for people who have a cytomegalovirus infection after a stem cell transplant. It aims to see if the drug safely clears the virus.
This study looks at the medication maribavir for people who have a CMV infection after a transplant that is not getting better with current treatments. The goal is to see how well maribavir works in this situation.
This Phase 3 trial tests maribavir (an anti-CMV medicine) in children and teens who get CMV infection after a stem cell or solid organ transplant. It aims to see whether the drug is safe and well-tolerated, and whether it can reduce the virus in the body.
This trial tests a new drug, maribavir, for controlling or treating active CMV infection in people with certain blood cancers (multiple myeloma, follicular lymphoma, or large B-cell lymphoma) who are taking a bispecific antibody therapy. The goal is to see if maribavir is safe and effective for managing CMV in this specific situation.
This study looks at how well the drug maribavir works in adults with kidney failure who get a CMV infection after a transplant. It focuses on people whose CMV infection hasn't responded to other treatments.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.